Welcome to Oncternal Therapeutics

 

With a pipeline that includes two clinical-stage products, we’re committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types.


Latest Release

 

In the News

 

Clinical-Stage Products
for Rare Cancers

We are recruiting patients

  • With CLL for a Phase 1 study of Cirmtuzumab, our anti-ROR1 monoclonal antibody
  • With Ewing sarcoma for a Phase 1 study of TK216, our small molecule inhibitor of ets-family transcription factor oncoproteins
Participate in Our Trial